🔬 The new microcarriers offer up to 60 times the surface area of traditional carriers, improving cell density and viral vector yields. Cellevate aims to launch this innovation at BIO-Europe in Stockholm.
Introduction:
The article discusses the recent successful scale-up of Cellevate’s Cellevat3d® nanofiber microcarriers at the Testa Center in Uppsala, Sweden. Funded by Vinnova/STUNS Life Science, this study marks a significant advancement in bioprocessing technologies, highlighting the product’s potential in cell culture systems for biomanufacturing applications, particularly in gene therapy and vaccine production.
- Cellevate successfully scaled up its nanofiber microcarriers using a 10-L Xcellerex XDR-10 single-use stirred tank bioreactor.
- The Cellevat3d microcarriers offer up to 60 times the surface area of traditional carriers, facilitating enhanced cell culture environments.
- This technology significantly improves viable cell densities and viral vector yields, providing a versatile option for industrial bioprocessing needs.
- The ease of use and implementation of this microcarrier in bioreactors was demonstrated without altering existing cell culture parameters.
- The official launch of these nanofiber microcarriers is planned to take place at the BIO-Europe conference in Stockholm.
Conclusion:
The scale-up of Cellevat3d nanofiber microcarriers represents a noteworthy progression in bioprocessing methodologies, with implications for more efficient cell culture solutions in the biotech industry. By enabling higher yields and improved operational frameworks, Cellevate is poised to contribute significantly to advancements in cell and gene therapy commercialization. Their upcoming launch will further highlight these innovations within a wider market context.
